O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide

Cancer
Emmanuèle Lechapt-ZalcmanJean-Sébastien Guillamo

Abstract

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation status was proposed as a prognostic biomarker for patients with glioblastoma. However, the prognostic impact of MGMT in patients with newly diagnosed glioblastoma who receive carmustine-releasing wafers (Gliadel) along with temozolomide (TMZ) is still unknown. MGMT promoter methylation status and protein expression were analyzed in formalin-fixed, paraffin-embedded tumor specimens obtained from 111 French patients with newly diagnosed glioblastoma. Patients received the Gliadel wafers followed by radiotherapy plus concomitant and adjuvant TMZ chemotherapy while they were enrolled in a French multicenter prospective study. For the whole cohort, the median overall survival (OS) was 17.5 months, and the progression-free survival was 10.3 months. Patients with tumors that harbored MGMT methylation had a significantly longer OS compared with patients who had wild-type MGMT (21.7 months vs 15.1 months; P = .025). Similarly, patients who had low MGMT protein expression (≤15%) had a significantly improved OS compared with patients who had high MGMT expression (27.0 months vs 15.1 months; P = .021). The extent of resection was the strongest clinical predictor of outco...Continue Reading

References

Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marta BrellFrancesc Graus
Jan 30, 2007·Laboratory Investigation; a Journal of Technical Methods and Pathology·Milena CankovicRichard J Zarbo
Dec 3, 2008·Journal of Neurosurgery·Matthew J McGirtAlfredo Quiñones-Hinojosa
Jun 23, 2009·Cancer Investigation·Jamal ShamsaraJavad Behravan
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Oct 21, 2009·Journal of Neuro-oncology·Lucie Karayan-TaponCatherine Gratas-Rabbia-Ré
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J van den BentJohan M Kros
May 6, 2010·Annals of Surgical Oncology·Philippe MeneiUNKNOWN Neuro-oncology Club of the French Society of Neurosurgery
Nov 26, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Davide SciuscioMonika E Hegi

❮ Previous
Next ❯

Citations

Nov 19, 2014·CNS Drugs·Riccardo SoffiettiRoberta Rudà
Jun 22, 2012·Acta neurochirurgica·Domenico d'Avella, Alessandro DellaPuppa
Nov 19, 2013·Expert Review of Anticancer Therapy·Amade BregyRicardo J Komotar
Jun 3, 2015·International Journal of Oncology·Giulio CabriniRoberto Gambari
Aug 8, 2015·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Rachel GrossmanHenry Brem
Jan 9, 2014·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Masaya MiyazakiShinya Tanaka
Aug 15, 2015·Journal of the American Chemical Society·Jessica L RougeChad A Mirkin
Oct 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·Urvashi M UpadhyayRobert Langer
Mar 10, 2015·Neuro-oncology·Scott D WaitAnthony L Asher
Jun 22, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Takuya ToyonagaTamaki Nagara
Jan 30, 2015·Journal of Neuro-oncology·Sajeel A ChowdharyHerbert B Newton
Jan 24, 2019·Neurosurgical Review·Tokunori KanazawaHikaru Sasaki
Jul 22, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Roberta RudàRiccardo Soffietti
May 7, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Chih-Yi HsuDonald Ming-Tak Ho
Nov 14, 2014·Journal of Neuro-oncology·Chih-Yi HsuDonald Ming-Tak Ho
Jan 13, 2015·Journal of Neuro-oncology·Chih-Yi HsuDonald Ming-Tak Ho
Mar 20, 2016·Cellular and Molecular Neurobiology·Robert C RennertBob S Carter
Jul 8, 2016·International Journal of Clinical Oncology·Megumi UtoMasahiro Hiraoka
Mar 8, 2017·Journal of Cellular Physiology·Maryam Moradi BinabajAmir Avan
Apr 5, 2017·Proceedings of the National Academy of Sciences of the United States of America·Timothy L SitaAlexander H Stegh
Oct 7, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rui-Chao ChaiYong-Zhi Wang
Jun 23, 2016·Molecular and Clinical Oncology·Junya FukaiNaoyuki Nakao
Feb 13, 2014·Journal of Neuro-oncology·Valentina FianoFranco Merletti
Feb 27, 2014·Molecular Cancer Therapeutics·Erika L MoenLucy A Godley
Dec 17, 2020·Pharmaceutics·Jessica I GriffithWilliam F Elmquist

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.